Tukysa

Phase 2

Tucatinib

Seagen Inc. (SGEN)

Fast TrackBreakthrough TherapyLearn about designations

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in HER2+ Breast Cancer

View Full Landscape

Drug Information

Target Indication

HER2+ Breast Cancer

Mechanism of Action

HER2 Kinase Inhibitor

Clinical Trial

NCT02614794

Last updated: 12/3/2025

Patent & Exclusivity

ActiveRLD

Latest Patent Expiry

Apr 27, 2038(11y 7m)

Patents Listed

Exclusivity

I-906ODE-309ODE-422

Application

NDA 213411

Source: FDA Orange Book

Regulatory Approvals

EMA2/11/2021

Tukysa

Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2?positive locally advanced or metastatic breast cancer who have received at least 2 prior anti-HER2 treatment regimens.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SGEN

Seagen Inc.

Biotechnology•North America•NASDAQ

Related Pipeline

PadcevPhase 3

Urothelial Cancer

sigvotatug vedotinPhase 3

Carcinoma, Non-Small-Cell Lung

tucatinibPhase 3

Gastric Adenocarcinoma

brentuximab vedotinPhase 3

Lymphoma, B-Cell

disitamab vedotinPhase 3

Breast Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts